Vulcan Value Partners LLC Has $103.24 Million Stake in Medpace Holdings, Inc. $MEDP

Vulcan Value Partners LLC lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,172 shares of the company’s stock after selling 87,287 shares during the period. Medpace comprises about 1.9% of Vulcan Value Partners LLC’s portfolio, making the stock its 19th largest holding. Vulcan Value Partners LLC owned 0.71% of Medpace worth $103,241,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Clarkston Capital Partners LLC bought a new position in Medpace in the second quarter valued at approximately $40,569,000. Cibc World Market Inc. acquired a new position in shares of Medpace in the third quarter valued at $5,033,000. Brighton Jones LLC raised its position in shares of Medpace by 160.4% in the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after purchasing an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Medpace by 150.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after buying an additional 9,117 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its holdings in shares of Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares during the period. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 122,720 shares of company stock worth $74,312,523 over the last quarter. Insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and lowered their target price for the stock from $462.00 to $419.00 in a research note on Wednesday. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Leerink Partners lowered their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a research report on Tuesday, February 10th. Four analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $483.45.

Medpace Stock Performance

Shares of MEDP stock opened at $453.77 on Monday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The stock’s fifty day moving average price is $556.01 and its two-hundred day moving average price is $539.44. The company has a market cap of $12.88 billion, a PE ratio of 29.66, a P/E/G ratio of 2.17 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s revenue was up 32.0% compared to the same quarter last year. During the same period last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.